{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-23-000071","form_type":"8-K/A","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.165285+00:00","generated_at":"2026-06-11T00:29:50.029569+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Skye Bioscience appoints Schwab and Grayson to board; Grayson gets $350k bonus and large performance RSUs","bullets":["Paul Grayson appointed director with a $350,000 sign-on bonus.","18.1M performance RSUs vest on market cap milestones: $125M, $250M, $400M, or $500M+ exit.","Additional 43.4M performance RSUs subject to stockholder approval of plan amendment.","Andrew Schwab appointed to board and compensation committee; standard non-employee director compensation.","7.4M stock options granted to non-employee directors; up to 17.6M more pending plan amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-23-000071","json":"https://secwatch.observer/filing/0001516551-23-000071.json","markdown":"https://secwatch.observer/filing/0001516551-23-000071.md","text":"https://secwatch.observer/filing/0001516551-23-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/0001516551-23-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/skye-20230815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:29:50.029569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"335296e1ed","claim":"Andrew Schwab was appointed as Director at Skye Bioscience, Inc..","evidence_excerpt":"Andrew Schwab and Paul Grayson were appointed to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/0001516551-23-000071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cc46c98cd7","claim":"Paul Grayson was appointed as Director at Skye Bioscience, Inc..","evidence_excerpt":"Andrew Schwab and Paul Grayson were appointed to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/0001516551-23-000071-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}